Download full-text PDF

Source

Publication Analysis

Top Keywords

[calcium antagonists
4
antagonists therapy
4
therapy essential
4
essential arterial
4
arterial hypertension
4
hypertension analysis
4
analysis drugs]
4
[calcium
1
therapy
1
essential
1

Similar Publications

İnsanlığın karşı karşıya kaldığı en önemli halk sağlığı sorunlarından biri olan ilaç direnci, antilayşmanyal ajan geliştirmede yeni stratejileri ve yaklaşımları zorunlu kılmaktadır. Dışa atım pompa inhibitörleri (DAPİ) ve diğer aday ajanlar ile ilgili gelişmeler umut verici olmakla birlikte, mevcut antilayşmanyallerin kullanım sürelerini ve etkinliklerini artırabilme arayışları da devam etmektedir. Bu çalışmada rezerpin (REZ), berberin (BER) ve verapamil (VER) olmak üzere üç adet DAPİ'nin antilayşmanyallere etkisinin araştırılması amaçlanmıştır.

View Article and Find Full Text PDF

From Atrial Small-conductance Calcium-activated Potassium Channels to New Antiarrhythmics.

Eur Cardiol

December 2024

Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen Copenhagen, Denmark.

Despite significant advances in its management, AF remains a major healthcare burden affecting millions of individuals. Rhythm control with antiarrhythmic drugs or catheter ablation has been shown to improve symptoms and outcomes in AF patients, but current treatment options have limited efficacy and/or significant side-effects. Novel mechanism-based approaches could potentially be more effective, enabling improved therapeutic strategies for managing AF.

View Article and Find Full Text PDF

GABA receptor (GABAR) activation is known to alleviate pain by reducing neuronal excitability, primarily through inhibition of high voltage-activated (HVA) calcium (Ca2.2) channels and potentiating G protein-coupled inwardly rectifying potassium (GIRK) channels. Although the analgesic properties of small molecules and peptides have been primarily tested on isolated murine dorsal root ganglion (DRG) neurons, emerging strategies to develop, study, and characterise human pluripotent stem cell (hPSC)-derived sensory neurons present a promising alternative.

View Article and Find Full Text PDF

The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarcinoma therapy.

Eur J Pharmacol

January 2025

Université Paris-Est, Immunorégulation et Biothérapie, INSERM U955, Hôpital Henri Mondor, 94010 Créteil, France; AP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Centre d'investigation clinique Biotherapie, F-94010 Creteil, France. Electronic address:

Pancreatic cancer (PCa) is one of the most devastating cancers with few clinical signs and no truly effective therapy. In recent years, our team has demonstrated that nucleolin antagonists such as N6L could be a therapeutic alternative for this disease. In order to study a possible clinic development of N6L (multivalent pseudopeptide), we undertook to study the effect of combination of N6L with chemotherapies classically used for PCa on the survival of pancreatic cancer cells.

View Article and Find Full Text PDF

Background: Pharmacotherapy of chronic kidney disease (CKD) consists of prescribing myriad of drugs such as antihypertensives, antidiabetics, and phosphate binders to delay disease progression and control the comorbidities, resulting in inherent variability in prescriptions. In addition, tendency to self-medicate may further aggravate the condition. Hence, the present study was planned to assess self-medication practices and variability in prescription patterns in CKD patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!